Our pipeline is focused on areas for which the unmet medical need is high, the biological rationale for treatment is clear, and for which there are few approved therapies, or where the standard of care is suboptimal. Our pipeline of anti-infective agents is one of the most unique in the industry and consists of four complementary compounds. Spero Therapeutics is advancing two lead programs in parallel, SPR994 and SPR741.
- SPR994 is a first in class oral agent that has demonstrated potent in vitro and in vivo activity against a wide variety of Gram-negative bacteria, including extended-spectrum beta-lactamases (ESBLs), and Gram-positive bacteria.
SPR741, also called Potentiator, allows for a platform approach to combination therapy to treat serious and life-threatening multi-drug resistant Gram-negative infections, such as Enterobacteriaceae.
